MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/bjh.12876

Медицинская библиотека · British journal of haematology · 2014

Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.

Sánchez-García Joaquín, Del Cañizo Consuelo, Lorenzo Ignacio, Nomdedeu Benet, Luño Elisa, de Paz Raquel, Xicoy Blanca, Valcárcel David, Brunet Salut, Marco-Betes Victor, García-Pintos Marta, Osorio Santiago, Tormo Mar, Bailén Alicia, Cerveró Carlos, Ramos Fernando, Diez-Campelo María, Such Esperanza, Arrizabalaga Beatriz, Azaceta Gemma, Bargay Joan, Arilla María J, Falantes José, Serrano-López Josefina, Sanz Guillermo F, Spanish Group on Myelodysplastic Syndromes (GES MD)

Сравнительное исследованиеСтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

The impact of lenalidomide treatment on long-term outcomes of patients with lower risk myelodysplastic syndromes (MDS) and chromosome 5q deletion (del(5q)) is unclear. This study used time-dependent multivariate methodology to analyse the influence of lenalidomide therapy on overall survival (OS) and acute myeloblastic leukaemia (AML) progression in 215 patients with International Prognostic Scoring System (IPSS) low or intermediate-1 risk and del(5q). There were significant differences in several relevant characteristics at presentation between patients receiving (n = 86) or not receiving lenalidomide (n = 129). The 5-year time-dependent probabilities of OS and progression to AML were 62% and 31% for patients receiving lenalidomide and 42% and 25% for patients not receiving lenalidomide; differences were not statistically significant in multivariate analysis that included all variables independently associated with those outcomes (OS, P = 0·45; risk of AML, P = 0·31, respectively). Achievement of RBC transfusion independency (P = 0·069) or cytogenetic response (P = 0·021) after lenalidomide was associated with longer OS in multivariate analysis. These data clearly show that response to lenalidomide results in a substantial clinical benefit in lower risk MDS patients with del(5q). Lenalidomide treatment does not appear to increase AML risk in this population of patients.

Для цитирования: Sánchez-García Joaquín, Del Cañizo Consuelo, Lorenzo Ignacio, Nomdedeu Benet, Luño Elisa, de Paz Raquel, Xicoy Blanca, Valcárcel David, Brunet Salut, Marco-Betes Victor, García-Pintos Marta, Osorio Santiago, Tormo Mar, Bailén Alicia, Cerveró Carlos, Ramos Fernando, Diez-Campelo María, Such Esperanza, Arrizabalaga Beatriz, Azaceta Gemma, Bargay Joan, Arilla María J, Falantes José, Serrano-López Josefina, Sanz Guillermo F, Spanish Group on Myelodysplastic Syndromes (GES MD). Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.. British journal of haematology. 2014. DOI: 10.1111/bjh.12876.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.